INHIBIKASE THERAPEUTICS, INC.

Company

Inhibikase Therapeutics, Inc.

Filed

October 10, 2024

Accession Number

0000902664-24-005789

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →